Verteporfin, a photodynamic therapy that is FDA-approved for macular degeneration, has been shown to disrupt the YAP-TEAD complex by directly inhibiting YAP and has been the most widely used “YAP inhibitor” in pre-clinical studies of YAP driven cancers [159,160]. Here, YAP1 is linked to cancer.